P14.19 Preclinical and clinical efficacy of entrectinib in primary and metastatic brain tumors harboring NTRK, ROS1, or ALK gene fusions

由 Rangaraju, S., Farago, A., Heym, K. M., Ahn, M., Drilon, A., Potts, S., Hornby, Z., Multani, P., Li, G.
發表在 Neuro Oncol (2017)

Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study

由 Hong, D S, Bauer, T M, Lee, J J, Dowlati, A, Brose, M S, Farago, A F, Taylor, M, Shaw, A T, Montez, S, Meric-Bernstam, F, Smith, S, Tuch, B B, Ebata, K, Cruickshank, S, Cox, M C, Burris, H A, Doebele, R C
發表在 Ann Oncol (2019)

What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC)

由 Drilon, A., Li, G., Dogan, S., Gounder, M., Shen, R., Arcila, M., Wang, L., Hyman, D. M., Hechtman, J., Wei, G., Cam, N. R., Christiansen, J., Luo, D., Maneval, E. C., Bauer, T., Patel, M., Liu, S. V., Ou, S. H. I., Farago, A., Shaw, A., Shoemaker, R. F., Lim, J., Hornby, Z., Multani, P., Ladanyi, M., Berger, M., Katabi, N., Ghossein, R., Ho, A. L.
發表在 Ann Oncol (2016)

Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children

由 Drilon, A., Laetsch, T.W., Kummar, S., DuBois, S.G., Lassen, U.N., Demetri, G.D., Nathenson, M., Doebele, R.C., Farago, A.F., Pappo, A.S., Turpin, B., Dowlati, A., Brose, M.S., Mascarenhas, L., Federman, N., Berlin, J., El-Deiry, W.S., Baik, C., Deeken, J., Boni, V., Nagasubramanian, R., Taylor, M., Rudzinski, E.R., Meric-Bernstam, F., Sohal, D.P.S., Ma, P.C., Raez, L.E., Hechtman, J.F., Benayed, R., Ladanyi, M., Tuch, B.B., Ebata, K., Cruickshank, S., Ku, N.C., Cox, M.C., Hawkins, D.S., Hong, D.S., Hyman, D.M.
發表在 N Engl J Med (2018)